DISEASE SCANNER
Global Incurable Diseases Tracker
Vitiligo
An autoimmune disorder characterized by loss of melanocytes resulting in depigmented patches of skin and hair. Affects 0.5-2% of global population. Can be segmental (limited) or non-segmental (generalized). Associated with other autoimmune diseases.
70.0M
111
Symptoms
Treatment Options
Risk Factors
Diagnostic Methods
- 1Clinical examination
- 2Wood's lamp examination
- 3Skin biopsy (rarely)
- 4Thyroid function tests
- 5Assessment for other autoimmune diseases
Prognosis
Chronic condition; unpredictable course. Some patients achieve repigmentation with treatment, especially facial lesions. Extensive disease more resistant. Emotional impact often significant. No cure currently.
Prevention
- Sun protection
- Avoid trauma to skin
- Early treatment
- Stress management
- Screening for associated autoimmune conditions
Research Status
Ruxolitinib cream (JAK inhibitor) first FDA-approved treatment for vitiligo. Protopic and Elidel (calcineurin inhibitors) for face. NB-UVB phototherapy. Afamelanotide implant. JAK inhibitors (tofacitinib) showing promise. Excimer laser.
Affected Countries
Sources
- https://www.cdc.gov/
- https://www.hematology.org/education/patients
- https://www.ncbi.nlm.nih.gov/books
- https://rarediseases.org/rare-diseases
Medical Disclaimer
This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.